

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Race Oncology Limited
ABN	61 149 318 749

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Chris Ntoumenopoulos
Date of last notice	12 February 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	<ol style="list-style-type: none"> Direct Indirect Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<ol style="list-style-type: none"> Sobol Capital Pty Ltd <BOC Investment A/C> – director related entity Mr Chris Ntoumenopoulos & Mr Leo Ntoumenopoulos <Ntoumenopoulos S/F A/C> - sole beneficiary
Date of change	14 October 2019
No. of securities held prior to change	<ol style="list-style-type: none"> 53,847 Ordinary Shares 506,250 Ordinary Shares 1,000,000 options exercisable at \$0.49, expiring 22 November 2019 1,000,000 options exercisable at \$0.65, expiring 22 November 2019 100,000 Ordinary Shares
Class	Ordinary Shares & Options exercisable at \$0.099, expiring 31/08/2021
Number acquired	<ol style="list-style-type: none"> 378,787 Ordinary Shares 189,393 Options
Number disposed	-
Value/Consideration includes brokerage/gst <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$25,000 Ordinary Shares. Nil Options.

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	<ol style="list-style-type: none"> 53,847 Ordinary Shares 506,250 Ordinary Shares 1,000,000 options exercisable at \$0.49, expiring 22 November 2019 1,000,000 options exercisable at \$0.65, expiring 22 November 2019 478,787 Ordinary Shares 189,393 Options exercisable at \$0.099, expiring 31/08/2021
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of placement shares and free attaching options as approved by shareholders on 09/10/2019

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.